

## ASX ANNOUNCEMENT



ASX Code: ESE

13 March 2019

### **eSense Lab Receives Order for Additional Shipment of Terpenes to UK-based E-liquid Company E-Quits**

#### **Investment Highlights**

- **Additional shipment of terpenes sent to United Kingdom-based E-Quits Group**
- **The shipment further cements e-Sense Lab's position as a key developer of products for the e-cigarette liquids, food additives and supplement markets**
- **The Commercial Supply Agreement marked a significant milestone in the Company's ongoing commercialisation activities and provides opportunities to expand product distribution to new global markets**

Life science company **eSense-Lab Limited (ASX:ESE)** ("**eSense**" or "**the Company**") is pleased to announce that it will provide an additional shipment of terpenes to the United Kingdom-based company E-Quits Group.

The order was received for a further two litres under the terms of the Commercial Supply Agreement eSense announced on 23 October 2018. The order is for a new shipment of materials based on the Company's Super Lemon Haze product for distribution in the United Kingdom. US\$5,000 was paid in advance for this order.

The Company expects an increase in shipments of its terpene blends as e-Quits continues to expand its distribution and sales of its products in the UK, opening further growth channels to global markets.

eSense's product continues to receive positive responses from E-Quits customers. The product is aimed at alleviation of anxiety, depression, pain relief (back injuries and arthritis) and most importantly, severe epileptic seizures. E-Quits, which has made a significant investment in the marketing and distribution of eSenses's product, has also paid in advance for this shipment of terpenes.

E-Quits is one of the largest companies operating in the UK e-liquid market, acquiring other e-liquid manufacturers such as Lonjas UK and Proof E-liquids and establishing a retail distribution company called Vaping Warehouse.

**eSense's CEO Haim Cohen said:** "We are very pleased to have sent an additional shipment of our innovative terpene product to e-Quits Group. The sustained supply of our products to e-Quits is important as it points to the continued stability of having recurring orders for our terpenes. E-Quits Group is one of the largest companies operating in the UK e-liquid market and recurring orders for our products show the satisfaction and trust our client has in our products. I look forward to informing the market of our upcoming activities and successes".

**ENDS**

---

**For further information, please contact:**

**Company Secretary**

Ian Pamensky  
+61 414 864 746  
[ian@cfo2grow.com.au](mailto:ian@cfo2grow.com.au)

**Media & Investor Enquiries**

Julia Maguire  
+61 419 815 386  
[julia@thecapitalnetwork.com.au](mailto:julia@thecapitalnetwork.com.au)

**Corporate Advisor**

EverBlu Capital  
+61 2 8249 0000  
[info@everblucapital.com](mailto:info@everblucapital.com)

**About eSense-Lab | Registered Office: Level 14, 330 Collins Street, Melbourne, Victoria, Australia, 3000**

eSense-Lab Ltd (ASX:ESE) is a life sciences research and development company creating natural plant-based products that heal and delight. Headquartered in Israel, eSense-Lab combines genetics, mRNA, protein expression and phytochemical profiles to generate a comprehensive model of rare or high value plants.

With multi-disciplinary R&D expertise, unique reverse engineering capabilities and game-changing techniques that enable re-engineering the chemical composition found in plants, e-Sense Lab re-formulates these for numerous commercial applications.

Cannabis is the first plant eSense is targeting for re-engineering. eSense is creating a cannabis plant that has all the characteristics of the real thing but does not contain the psychoactive and more heavily regulated cannabinoid compound.

To learn more about eSense-Lab, please visit [www.esense-lab.com](http://www.esense-lab.com)